New injection could tame seasonal allergy symptoms for those failed by standard treatments

NCT ID NCT07688772

First seen Jul 07, 2026 · Last updated Jul 08, 2026 · Updated 1 time

Summary

This Phase 3 trial tests an investigational injection called SHR-1819 in adults aged 18 to 75 with seasonal allergic rhinitis (hay fever) who haven't gotten enough relief from standard treatments like nasal sprays or antihistamines. The study compares the drug to a placebo to see if it reduces nasal symptoms such as sneezing and congestion, as well as eye symptoms, over two to four weeks. Researchers will also monitor safety and how the body processes the drug.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
SHR-1819 injection
What this could lead to
If effective, SHR-1819 could offer a new treatment option for people with seasonal allergies who don't get relief from standard nasal sprays or antihistamines.
What could go wrong
This is an early Phase 3 trial, so the drug may not prove more effective than placebo. Side effects are possible, and results may not apply to all allergy sufferers.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SEASONAL ALLERGIC RHINITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Beijing Tongren Hospital, Capital Medical University

    Beijing, Beijing Municipality, 100005, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

More trials for these conditions

Other studies related to the condition(s) this trial covers.